

Fang Zhou

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6353549/publications.pdf>

Version: 2024-02-01

17
papers

553
citations

759233

12
h-index

888059

17
g-index

17
all docs

17
docs citations

17
times ranked

1067
citing authors

#	ARTICLE	IF	CITATIONS
1	Targeting tumor endothelial hyperglycolysis enhances immunotherapy through remodeling tumor microenvironment. <i>Acta Pharmaceutica Sinica B</i> , 2022, 12, 1825-1839.	12.0	9
2	Target-responsive subcellular catabolism analysis for early-stage antibody-drug conjugates screening and assessment. <i>Acta Pharmaceutica Sinica B</i> , 2021, 11, 4020-4031.	12.0	3
3	Disrupted hepatic pentose phosphate pathway directly participates in and indirectly promotes CYP3A reduction: A new strategy for CYP3A-mediated drug hepatotoxicity. <i>British Journal of Pharmacology</i> , 2020, 177, 1538-1555.	5.4	4
4	Identification of bioactive anti-angiogenic components targeting tumor endothelial cells in Shenmai injection using multidimensional pharmacokinetics. <i>Acta Pharmaceutica Sinica B</i> , 2020, 10, 1694-1708.	12.0	27
5	Apatinib induces β -hydroxybutyric acid production in the liver of mice by peroxisome proliferator-activated receptor α activation to aid its antitumor effect. <i>Cancer Science</i> , 2019, 110, 3328-3339.	3.9	26
6	Sensitive analysis and pharmacokinetic study of a novel gemcitabine carbamate prodrug and its active metabolite gemcitabine in rats using LC-ESI-MS/MS. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2018, 1083, 249-257.	2.3	5
7	Application of liquid chromatography-tandem mass spectrometry to study the effect of docetaxel on pharmacokinetics and tissue distribution of apatinib in mice. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2018, 1083, 198-203.	2.3	10
8	Bevacizumab-enhanced antitumor effect of 5-fluorouracil via upregulation of thymidine phosphorylase through vascular endothelial growth factor A/vascular endothelial growth factor receptor 2-specificity protein 1 pathway. <i>Cancer Science</i> , 2018, 109, 3294-3304.	3.9	22
9	Combined treatment with apatinib and docetaxel in A549 xenograft mice and its cellular pharmacokinetic basis. <i>Acta Pharmacologica Sinica</i> , 2018, 39, 1670-1680.	6.1	17
10	LC-MS/MS method for the simultaneous determination of Lys-MCC-DM1, MCC-DM1 and DM1 as potential intracellular catabolites of the antibody-drug conjugate trastuzumab emtansine (T-DM1). <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2017, 137, 170-177.	2.8	18
11	The down-regulation of SLC7A11 enhances ROS induced P-gp over-expression and drug resistance in MCF-7 breast cancer cells. <i>Scientific Reports</i> , 2017, 7, 3791.	3.3	49
12	Conjugation site analysis of antibody-drug-conjugates (ADCs) by signature ion fingerprinting and normalized area quantitation approach using nano-liquid chromatography coupled to high resolution mass spectrometry. <i>Analytica Chimica Acta</i> , 2017, 955, 67-78.	5.4	31
13	Chronic inflammation up-regulates P-gp in peripheral mononuclear blood cells via the STAT3/NF- κ B pathway in 2,4,6-trinitrobenzene sulfonic acid-induced colitis mice. <i>Scientific Reports</i> , 2015, 5, 13558.	3.3	40
14	Metabolomic approach to evaluating adriamycin pharmacodynamics and resistance in breast cancer cells. <i>Metabolomics</i> , 2013, 9, 960-973.	3.0	66
15	Stereoselective Regulations of P-Glycoprotein by Ginsenoside Rh2 Epimers and the Potential Mechanisms From the View of Pharmacokinetics. <i>PLoS ONE</i> , 2012, 7, e35768.	2.5	33
16	Cellular pharmacokinetic mechanisms of adriamycin resistance and its modulation by 20(S)-ginsenoside Rh2 in MCF-7/Adr cells. <i>British Journal of Pharmacology</i> , 2012, 165, 120-134.	5.4	73
17	Differences in metabolite profile between blood plasma and serum. <i>Analytical Biochemistry</i> , 2010, 406, 105-112.	2.4	120